Antibody C region influences TGN1412-like functional activity in vitro

Journal of Immunology

Volumn 189, Issue 12, 2012, Pages 5831-5840

  Ball, Christina ^a   Fox, Bernard ^a   Hufton, Simon ^a   Sharp, Giles ^a   Poole, Stephen ^a   Stebbings, Richard ^a   Eastwood, David ^a   Findlay, Lucy ^a   Parren, Paul W H I ^b   Thorpe, Robin ^a   Bristow, Adrian ^a   Thorpe, Susan J ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b GENMAB   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; FC RECEPTOR; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; INTERFERON; INTERLEUKIN 2; MONOCLONAL ANTIBODY; TGN 1412; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG PROTEIN BINDING; FLOW CYTOMETRY; IMMOBILIZATION; IN VITRO STUDY; MACACA; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BINDING SITES, ANTIBODY; CELL PROLIFERATION; CELLS, CULTURED; CLINICAL TRIALS, PHASE I AS TOPIC; COCULTURE TECHNIQUES; CYTOKINES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOGLOBULIN CONSTANT REGIONS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN FC FRAGMENTS; LEUKOCYTES, MONONUCLEAR; MACACA FASCICULARIS; PROTEIN BINDING; RECEPTORS, IGG; RECOMBINANT PROTEINS;

EID: 84871122818     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201795     Document Type: Article

References (52)

1. Salfeld, J. G. 2007. Isotype selection in antibody engineering. Nat. Biotechnol. 25: 1369-1372. (Pubitemid 350233124)
2. Swann, P. G., M. Tolnay, S. Muthukkumar, M. A. Shapiro, B. L. Rellahan, and K. A. Clouse. 2008. Considerations for the development of therapeutic monoclonal antibodies. Curr. Opin. Immunol. 20: 493-499.
3. TeGenero, A. G. Investigator's Brochure. TGN1412 Humanized Agonistic Anti-CD28 Monoclonal Antibody. Edition 1.1. Available at: http://www.circare. org/foia5/tgn1412investigatorbrochure.pdf. Accessed: October 24, 2010.
4. Suntharalingam, G., M. R. Perry, S. Ward, S. J. Brett, A. Castello-Cortes, M. D. Brunner, and N. Panoskaltsis. 2006. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355: 1018-1028. (Pubitemid 44343545)
5. Medicines and Healthcare Products Regulatory Agency (MHRA). Investigations into Adverse Incidents during Clinical Trials of TGN1412. Available at: http://www.circare.org/foia5/tgn1412rptfinal-20060525.pdf. Accessed: October 24, 2012.
6. Stebbings, R., L. Findlay, C. Edwards, D. Eastwood, C. Bird, D. North, Y. Mistry, P. Dilger, E. Liefooghe, I. Cludts, et al. 2007. "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J. Immunol. 179: 3325-3331.
7. Sharpe, A. H., and A. K. Abbas. 2006. T-cell costimulation - biology, therapeutic potential, and challenges. N. Engl. J. Med. 355: 973-975. (Pubitemid 44343539)
8. Wise, M. P., A. Gallimore, and A. Godkin. 2006. T-cell costimulation. N. Engl. J. Med. 355: 2594-2595, author reply 2595.
9. Colaco, C. 2006. What went horribly wrong in a London clinical trial? Scientist 20: 14.
10. Labrijn, A. F., A. O. Buijsse, E. T. J. van den Bremer, A. Y. W. Verwilligen, W. K. Bleeker, S. J. Thorpe, J. Killestein, C. H. Polman, R. C. Aalberse, J. Schuurman, et al. 2009. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat. Biotechnol. 27: 767-771.
11. Eastwood, D., L. Findlay, S. Poole, C. Bird, M. Wadhwa, M. Moore, C. Burns, R. Thorpe, and R. Stebbings. 2010. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br. J. Pharmacol. 161: 512-526.
12. Findlay, L., G. Sharp, B. Fox, C. Ball, C. J. Robinson, C. Bird, R. Stebbings, D. Eastwood, M. Wadhwa, S. Poole, et al. 2011. Endothelial cells co-stimulate peripheral blood mononuclear cell responses to monoclonal antibody TGN1412 in culture. Cytokine 55: 141-151.
13. Römer, P. S., S. Berr, E. Avota, S.-Y. Na, M. Battaglia, I. ten Berge, H. Einsele, and T. Hünig. 2011. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood 118: 6772-6782.
14. Edelman, G. M., B. A. Cunningham, W. E. Gall, P. D. Gottlieb, U. Rutishauser, and M. J. Waxdal. 1969. The covalent structure of an entire gammaG immunoglobulin molecule. Proc. Natl. Acad. Sci. USA 63: 78-85.
15. Alegre, M.-L., A. M. Collins, V. L. Pulito, R. A. Brosius, W. C. Olson, R. A. Zivin, R. Knowles, J. R. Thistlethwaite, L. K. Jolliffe, and J. A. Bluestone. 1992. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. J. Immunol. 148: 3461-3468.
16. Angal, S., D. J. King, M. W. Bodmer, A. Turner, A. D. G. Lawson, G. Roberts, B. Pedley, and J. R. Adair. 1993. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol. Immunol. 30: 105-108. (Pubitemid 223036868)
17. Hanke, T. 2006. Use of an active substance binding to CD28 for producing a pharmaceutical composition for the treatment of B-CLL. United States Patent Application Publication. Available at: http://www.freepatentsonline.com/ 20060008457.pdf. Accessed: October 24, 2012.
18. Thorpe, S. J., C. Turner, A. Heath, I. Feavers, I. Vatn, J. B. Natvig, and K. M. Thompson. 2003. Clonal analysis of a human antimouse antibody (HAMA) response. Scand. J. Immunol. 57: 85-92. (Pubitemid 38019092)
19. Goodrick, J., B. Kumpel, D. Pamphilon, I. Fraser, G. Chapman, B. Dawes, and D. Anstee. 1994. Plasma half-lives and bioavailability of human monoclonal Rh D antibodies BRAD-3 and BRAD-5 following intramuscular injection into Rh D-negative volunteers. Clin. Exp. Immunol. 98: 17-20. (Pubitemid 24315445)
20. Thorpe, S. J., C. Ball, B. Fox, K. M. Thompson, R. Thorpe, and A. Bristow. 2008. Anti-D and anti-i activities are inseparable in V4-34-encoded monoclonal anti-D: the same framework 1 residues are required for both reactivities. Transfusion 48: 930-940. (Pubitemid 351614904)
21. Council of Europe. 2012. Bacterial endotoxins. Method B, general chapter 2.6.14. In European Pharmacopoeia, 7th Ed. Council of Europe, Strasbourg, France.
22. Thorpe, S. J., and S. W. Bailey. 1993. Demonstration of autoreactivity by a human monoclonal IgG anti-Rh D antibody. Br. J. Haematol. 83: 311-318. (Pubitemid 23060929)
23. Hessell, A. J., L. Hangartner, M. Hunter, C. E. G. Havenith, F. J. Beurskens, J. M. Bakker, C. M. S. Lanigan, G. Landucci, D. N. Forthal, P. W. H. I. Parren, et al. 2007. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449: 101-104. (Pubitemid 47373775)
24. Rispens, T., P. Ooievaar-De Heer, E. Vermeulen, J. Schuurman, M. van der Neut Kolfschoten, and R. C. Aalberse. 2009. Human IgG4 binds to IgG4 and conformationally altered IgG1 via Fc-Fc interactions. J. Immunol. 182: 4275-4281.
25. Clark, M. R., S. B. Clarkson, P. A. Ory, N. Stollman, and I. M. Goldstein. 1989. Molecular basis for a polymorphism involving Fc receptor II on human monocytes. J. Immunol. 143: 1731-1734. (Pubitemid 19217445)
26. Salmon, J. E., J. C. Edberg, N. L. Brogle, and R. P. Kimberly. 1992. Allelic polymorphisms of human Fc gamma receptor IIA and Fc gamma receptor IIIB. Independent mechanisms for differences in human phagocyte function. J. Clin. Invest. 89: 1274-1281.
27. Parren, P.W., P. A. M.Warmerdam, L. C. M. Boeije, J. Arts, N. A. C.Westerdaal, A. Vlug, P. J. A. Capel, L. A. Aarden, and J. G. J. van de Winkel. 1992. On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J. Clin. Invest. 90: 1537-1546.
28. Findlay, L., D. Eastwood, R. Stebbings, G. Sharp, Y. Mistry, C. Ball, J. Hood, R. Thorpe, and S. Poole. 2010. Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412. J. Immunol. Methods 352: 1-12.
29. Reddy, M. P., C. A. S. Kinney, M. A. Chaikin, A. Payne, J. Fishman-Lobell, P. Tsui, P. R. Dal Monte, M. L. Doyle, M. R. Brigham-Burke, D. Anderson, et al. 2000. Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J. Immunol. 164: 1925-1933. (Pubitemid 30108747)
30. Newman, R., K. Hariharan, M. Reff, D. R. Anderson, G. Braslawsky, D. Santoro, N. Hanna, P. J. Bugelski, M. Brigham-Burke, C. Crysler, et al. 2001. Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees. Clin. Immunol. 98: 164-174.
31. van der Neut Kolfschoten, M., J. Schuurman, M. Losen, W. K. Bleeker, P. Martínez-Martínez, E. Vermeulen, T. H. den Bleker, L. Wiegman, T. Vink, L. A. Aarden, et al. 2007. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317: 1554-1557. (Pubitemid 47417435)
32. Labrijn, A. F., T. Rispens, J. Meesters, R. J. Rose, T. H. den Bleker, S. Loverix, E. T. J. van den Bremer, J. Neijssen, T. Vink, I. Lasters, et al. 2011. Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength. J. Immunol. 187: 3238-3246.
33. Bloom, J. W., M. S. Madanat, D. Marriott, T. Wong, and S.-Y. Chan. 1997. Intrachain disulfide bond in the core hinge region of human IgG4. Protein Sci. 6: 407-415. (Pubitemid 27079933)
34. Schuurman, J., G. J. Perdok, A. D. Gorter, and R. C. Aalberse. 2001. The interheavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds. Mol. Immunol. 38: 1-8. (Pubitemid 32718637)
35. Ito, T., K. Kitahara, T. Umemura, M. Ota, Y. Shimozuru, S. Kawa, and S. Bahram. 2010. A novel heterophilic antibody interaction involves IgG4. Scand. J. Immunol. 71: 109-114.
36. Stebbings, R., D. Eastwood, S. Poole, and R. Thorpe. 2012. After TGN1412: Recent developments in cytokine release assays. An article based on a presentation at the 20(th) Summerschool in Immunotoxicology, Beaune, France, September 26-28, 2011. J. Immunotoxicol. In press10.3109/1547691X.2012.711783.
37. Weissmüller, S., L. Y. Semmler, U. Kalinke, S. Christians, J. Müller-Berghaus, and Z. Waibler. 2012. ICOS-LICOS interaction is critically involved in TGN1412-mediated T-cell activation. Blood 119: 6268-6277.
38. McLean, G. R., M. Torres, N. Elguezabal, A. Nakouzi, and A. Casadevall. 2002. Isotype can affect the fine specificity of an antibody for a polysaccharide antigen. J. Immunol. 169: 1379-1386. (Pubitemid 34809182)
39. Torres, M., R. May, M. D. Scharff, and A. Casadevall. 2005. Variable-region-identical antibodies differing in isotype demonstrate differences in fine specificity and idiotype. J. Immunol. 174: 2132-2142. (Pubitemid 40223957)
40. (H)1 constant region domain modulate antigen binding affinity of antibodies? J. Clin. Invest. 98: 2235-2243.
41. Cooper, L. J. N., J. C. Schimenti, D. D. Glass, and N. S. Greenspan. 1991. H chain C domains influence the strength of binding of IgG for streptococcal group A carbohydrate. J. Immunol. 146: 2659-2663.
42. Lühder, F., Y. Huang, K. M. Dennehy, C. Guntermann, I. Müller, E. Winkler, T. Kerkau, S. Ikemizu, S. J. Davis, T. Hanke, and T. Hünig. 2003. Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J. Exp. Med. 197: 955-966. (Pubitemid 36523193)
43. Margulies, D. H. 2003. CD28, costimulator or agonist receptor? J. Exp. Med. 197: 949-953. (Pubitemid 36523192)
44. Collins, A. V., D. W. Brodie, R. J. C. Gilbert, A. Iaboni, R. Manso-Sancho, B. Walse, D. I. Stuart, P. A. van der Merwe, and S. J. Davis. 2002. The interaction properties of costimulatory molecules revisited. Immunity 17: 201-210. (Pubitemid 35245962)
45. Dennehy, K. M., F. Elias, G. Zeder-Lutz, X. Ding, D. Altschuh, F. Lühder, and T. Hünig. 2006. Cutting edge: monovalency of CD28 maintains the antigen dependence of T cell costimulatory responses. J. Immunol. 176: 5725-5729.
46. Dangl, J. L., T. G. Wensel, S. L. Morrison, L. Stryer, L. A. Herzenberg, and V. T. Oi. 1988. Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J. 7: 1989-1994.
47. Roux, K. H., L. Strelets, and T. E. Michaelsen. 1997. Flexibility of human IgG subclasses. J. Immunol. 159: 3372-3382. (Pubitemid 127482096)
48. Dubey, C., M. Croft, and S. L. Swain. 1996. Naive and effector CD4 T cells differ in their requirements for T cell receptor versus costimulatory signals. J. Immunol. 157: 3280-3289. (Pubitemid 126449137)
49. Sallusto, F., J. Geginat, and A. Lanzavecchia. 2004. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22: 745-763. (Pubitemid 38680440)
50. Wypych, J., M. Li, A. Guo, Z. Zhang, T. Martinez, M. J. Allen, S. Fodor, D. N. Kelner, G. C. Flynn, Y. D. Liu, et al. 2008. Human IgG2 antibodies display disulfide-mediated structural isoforms. J. Biol. Chem. 283: 16194-16205.
51. Dillon, T. M., M. S. Ricci, C. Vezina, G. C. Flynn, Y. D. Liu, D. S. Rehder, M. Plant, B. Henkle, Y. Li, S. Deechongkit, et al. 2008. Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J. Biol. Chem. 283: 16206-16215.
52. Yoo, E. M., L. A. Wims, L. A. Chan, and S. L. Morrison. 2003. Human IgG2 can form covalent dimers. J. Immunol. 170: 3134-3138. (Pubitemid 36302189)